Patent ID: 7323460

Claim:
A compound of Formula (I): wherein R 1′ is —H or —F; R 2′ is (1) —C 1-6 alkyl-C(═O)N(R a R b ), (2) —C(═O)N(R a R b ), (3) is azetidinyl, pyrrolidinyl, piperidinyl, or morpholino, (4) triazolyl or tetrazolyl, (5) —N(R a )—C(R b )═O, (6) wherein x1 is an integer equal to zero, 1, or 2, or (7) —CO 2 R c ; R 3′ is: (1) —H, (2) —C(═O)N(R a R b ), (3) —CH 2 —C(═O)N(R a R b ), (4) —CH 2 CH 2 —C(═O)N(R a R b ), (5) —S—CH 2 —C(═O)N(R a R b ), (6) —O—CH 2 —C(═O)N(R a R b ), (7) —N(R a )—C(R b )═O, (8) —N(SO 2 R c )—CH 2 —C(═O)N(R a R b ), (9) —N(R a )—C(═O)—C(═O)N(R a R b ), (10) —N(R a )SO 2 R c , (11) —CH═CH—C(═O)—N(R a R b ), (12) —N(R a )—CH 2 —C(═O)N(R a R b ), (13) —N(R a )—C(═O)—N(R a R b ), (14)-HetC′, (15) —(CH 2 ) 1-3 alkyl-HetC′, (16) —N(R a )—(CH 2 ) 1-3 -HetC′, (17) —N(R a )—SO 2 —N(R a R b ), (18)-HetQ′, (19) is as defined above in R 2′ , or (20) is as defined above in R 2′ ; HetC′ is a 5- to 7-membered saturated heterocyclic ring containing from 1 to 4 heteratoms independently selected from N, O and S, wherein the saturated heterocyclic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-4 alkyl, —C 3-6 cycloalkyl, —O—C 1-4 alkyl, —C 1-4 haloalkyl, —O—C 1-4 haloalkyl, —CN, oxo, phenyl, benzyl, phenylethyl, —(CH 2 ) 0-3 C(═O)N(R a R b ), —(CH 2 ) 0-3 C(═O)R a , —N(R a )—C(═O)R b , —N(R a )—CO 2 R b , —(CH 2 ) 1-3 N(R a )—C(═O)R b , —N(R a R b ), —(CH 2 ) 1-3 N(R a R b ), —SO 2 R c , —(CH 2 ) 0-3 C(═O)-HetD′, —HetD′, —N(R a )-HetD′, and —(CH 2 ) 1-3 -HetD′; wherein each HetD′ is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 nitrogen atoms or a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 nitrogen atoms, wherein the ring is optionally substituted with 1 or 2 substituents each of which is independently halogen, oxo, —C 1-4 alkyl, or —O—C 1-4 alkyl; HetQ′ is a 7- to 9-membered bridged azabicycloalkyl saturated ring system containing a C 5-7 azacycloalkyl ring in which two of the ring carbons are connected by a bridge containing 1 or 2 carbon atoms; wherein the bridged azabicycloalkyl ring system is optionally substituted with from 1 to 4 substituents each of which is independently halogen, oxo, or —C 1-4 alkyl; each R a is independently —H, —C 1-6 alkyl, or —C 3-6 cycloalkyl; each R b is independently —H, —C 1-6 alkyl, or —C 3-6 cycloalkyl; and each R c is independently a —C 1-6 alkyl or —C 3-6 cycloalkyl; or a pharmaceutically acceptable salt thereof.